Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHC Healthcare GroupTPE:4164 +1.34%79 EV-to-EBIT is 19.89 as of Aug. 26, 2026, which is 9% below its 10-year median of 21.83. GuruFocus rates TPE:4164 with a GF Score™ of 79/100 and a GF Value™ of NT$49.03 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 97 Medical Distribution companies, CHC Healthcare Group ranks worse than 75.26% on this metric.
CHC Healthcare Group (TPE:4164) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CHC Healthcare Group's Enterprise Value for the quarter that ended in Jun. 2026 was NT$10,252 Mil.
CHC Healthcare Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$493 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHC Healthcare Group EV-to-EBIT Related Terms
CHC Healthcare Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CHC Healthcare Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, CHC Healthcare Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHC Healthcare Group EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, CHC Healthcare Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CHC Healthcare Group's EV-to-EBIT falls into.
CHC Healthcare Group's current Enterprise Value is NT$9,803 Mil.
CHC Healthcare Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$493 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHC Healthcare Group (TPE:4164) has a EV-to-EBIT of 19.89 as of Aug. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CHC Healthcare Group and its competitors. This is near median its historical median of 21.83. According to the industry distribution chart, CHC Healthcare Group ranks #73 out of 97 companies in the Medical Distribution industry, placing it in the top 75.3%.
Is CHC Healthcare Group's EV-to-EBIT too high?
CHC Healthcare Group's current EV-to-EBIT of 19.89 is near median its 10-year median of 21.83. The Medical Distribution industry median EV-to-EBIT is 11.39. CHC Healthcare Group's value of 19.89 is 74.6% above this industry median. Based on the distribution chart, CHC Healthcare Group ranks #73 out of 97 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, CHC Healthcare Group has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CHC Healthcare Group's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, CHC Healthcare Group ranks #73 out of 97 companies for EV-to-EBIT. This places CHC Healthcare Group in the lower half of its industry. The industry median EV-to-EBIT is 11.39. CHC Healthcare Group's value of 19.89 is 74.6% above this benchmark. While the company's 10-year median is 21.83 vs. the industry median of 11.39, CHC Healthcare Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.39, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHC Healthcare Group's current EV-to-EBIT of 19.89 is 74.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CHC Healthcare Group and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHC Healthcare Group's current EV-to-EBIT is 19.89, which is near median its own 10-year median of 21.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHC Healthcare Group stock overvalued right now?
Based on GuruFocus' analysis, CHC Healthcare Group (TPE:4164) is currently considered Possible Value Trap. The stock's GF Value™ is NT$49.03, compared to a current price of NT$26.55 — trading 45.8% below its estimated fair value. The current EV-to-EBIT is 19.89, which is near median its 10-year median of 21.83 and 74.6% above the Medical Distribution industry median of 11.39. CHC Healthcare Group's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CHC Healthcare Group (TPE:4164), the current EV-to-EBIT is 19.89 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CHC Healthcare Group (TPE:4164) Overvalued in 2026?
Based on GuruFocus' analysis, CHC Healthcare Group stock appears to be undervalued.
The current stock price of NT$26.55 is trading 45.8% below its estimated GF Value™ of NT$49.03.
GuruFocus considers CHC Healthcare Group to be Possible Value Trap.
Key valuation signals for TPE:4164:
EV-to-EBIT: 19.89 (near median its 10-year median of 21.83)
GF Value™: NT$49.03 vs. price of NT$26.55 (45.8% below fair value)
Industry Position: 74.6% above the Medical Distribution median (#73 of 97)
No single metric tells the full story. See the TPE:4164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CHC Healthcare Group is a Taiwan-based company engaged in the trading of pharmaceutical products and health food, as well as the sale, leasing, installation, and repair of medical instruments. It is engaged in the distribution of radiotherapy equipment, including equipment used in radiation oncology, ophthalmology, dentistry, and neuroscience. It also provides medical equipment consulting for hospitals and clinics. It earns revenues from the sale of drugs, the sale of medical instruments, repairs, maintenance, and other services.
79GF Score
Get the complete analysis for TPE:4164
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4164 has been successfully added to your 
